title: Bad liver and a broken heart.
abstract: In this issue of Blood, the CORDELIA study presented by Pennell and colleagues shows that deferasirox (DFX; Exjade, Novartis) is not inferior to deferoxamine (DFO; Desferal, Novartis) for the removal of cardiac iron in β-thalassemia. CORDELIA also supports previous findings that efficacy of cardiac iron removal is better if liver iron concentration (LIC) is low.
authors.affiliation: CHILDREN'S HOSPITAL LOS ANGELES;
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Coates
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D000077588:Deferasirox; D003676:Deferoxamine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology*; D014230:Triazoles / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000150:complications*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D003676:Deferoxamine; D000077588:Deferasirox